Sapphire Ventures L.L.C. Sells 5,027,232 Shares of 23andMe Holding Co. (NASDAQ:ME)

Sapphire Ventures L.L.C. cut its holdings in 23andMe Holding Co. (NASDAQ:ME) by 95.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 264,592 shares of the company’s stock after selling 5,027,232 shares during the period. 23andMe makes up approximately 0.7% of Sapphire Ventures L.L.C.’s portfolio, making the stock its 5th biggest position. Sapphire Ventures L.L.C. owned approximately 1.01% of 23andMe worth $860,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ME. FNY Investment Advisers LLC bought a new position in shares of 23andMe during the fourth quarter valued at about $26,000. Leavell Investment Management Inc. bought a new position in 23andMe during the fourth quarter valued at $32,000. MassMutual Private Wealth & Trust FSB purchased a new stake in 23andMe in the fourth quarter worth $40,000. Geode Capital Management LLC increased its position in 23andMe by 0.7% in the third quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock worth $1,476,000 after buying an additional 28,252 shares during the last quarter. Finally, FMR LLC raised its stake in shares of 23andMe by 24.0% in the third quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after buying an additional 192,099 shares during the period. 36.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 23andMe in a report on Wednesday, February 19th.

23andMe Trading Up 0.5 %

ME opened at $2.20 on Friday. The stock has a market capitalization of $59.02 million, a P/E ratio of -0.14 and a beta of 1.14. 23andMe Holding Co. has a 12-month low of $2.10 and a 12-month high of $13.00. The stock has a 50-day moving average price of $3.11 and a 200-day moving average price of $4.46.

23andMe (NASDAQ:ME) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($1.02) EPS for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 170.07%.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.